Key facts
- This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
- 9 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2023, 16:14.
Stephane Bancel - 07 Jun 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MRNA
- Reported as of
- 07 Jun 2023
- Net transaction value
- -$9,913,584
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2023, 16:14:08 UTC
- Prior SEC filing
- 02 Jun 2023
- Next SEC filing
- 16 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Dillon, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 09 Jun 2023.
Change
- Previous filing in this sequence was filed on 02 Jun 2023.
- Current net transaction value: -$9,913,584.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $39,600
- Shares
- +40,000
- Change %
- +0.74%
- Price
- $0.9900*
- Shares after
- 5,451,946
- Date
- 07 Jun 2023
- Ownership
- Direct
- Footnotes
- F3
MRNA
transaction
Common Stock
Sale
- Transaction value
- $4,510,187
- Shares
- -35,872
- Change %
- -0.66%
- Price
- $125.73
- Shares after
- 5,416,074
- Date
- 07 Jun 2023
- Ownership
- Direct
- Footnotes
- F3, F4
MRNA
transaction
Common Stock
Sale
- Transaction value
- $522,233
- Shares
- -4,128
- Change %
- -0.08%
- Price
- $126.51
- Shares after
- 5,411,946
- Date
- 07 Jun 2023
- Ownership
- Direct
- Footnotes
- F3, F5
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $39,600
- Shares
- +40,000
- Change %
- +0.74%
- Price
- $0.9900*
- Shares after
- 5,451,946
- Date
- 08 Jun 2023
- Ownership
- Direct
- Footnotes
- F3
MRNA
transaction
Common Stock
Sale
- Transaction value
- $2,745,330
- Shares
- -22,215
- Change %
- -0.41%
- Price
- $123.58
- Shares after
- 5,429,731
- Date
- 08 Jun 2023
- Ownership
- Direct
- Footnotes
- F3, F6
MRNA
transaction
Common Stock
Sale
- Transaction value
- $2,166,324
- Shares
- -17,396
- Change %
- -0.32%
- Price
- $124.53
- Shares after
- 5,412,335
- Date
- 08 Jun 2023
- Ownership
- Direct
- Footnotes
- F3, F7
MRNA
transaction
Common Stock
Sale
- Transaction value
- $48,711
- Shares
- -389
- Change %
- -0.01%
- Price
- $125.22
- Shares after
- 5,411,946
- Date
- 08 Jun 2023
- Ownership
- Direct
- Footnotes
- F3, F8
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,050,372
- Date
- 07 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,564,880
- Date
- 07 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -40,000
- Change %
- -15%
- Price
- $0.000000
- Shares after
- 227,155
- Date
- 07 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $0.9900
- Footnotes
- F3, F9
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -40,000
- Change %
- -18%
- Price
- $0.000000
- Shares after
- 187,155
- Date
- 08 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $0.9900
- Footnotes
- F3, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F2
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F3
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.
Footnote F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.31 to $126.31. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.32 to $126.92. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F6
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.11 to $124.11. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F7
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.12 to $125.08. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F8
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.13 to $125.29. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F9
This option is fully vested and exercisable.